Morgan Stanley Feels Confidence in Charles River Laboratories Following Solid 4Q13 EPS Report

In a report published Wednesday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Equal-Weight rating on

. In the report, Morgan Stanley noted, “CRL reported 4Q13 EPS of $0.73 vs. cons/MS at $0.68 with beat driven by below the line items. Specifically, sources of upside vs. MS included sales (+$0.01), net int. (+$0.02), other inc. ($0.01), tax rate (+$0.04) and share count (+$0.01), offset by operating margin (-$0.04).” Charles River Laboratories closed on Tuesday at $57.99.